Synthesizing efficacious genistein in conjugation with superparamagnetic Fe 3 O 4 decorated with bio-compatible carboxymethylated chitosan against acute leukemia lymphoma
Source abstract
Abstract
Abstract Background Genistein (C 15 H 10 O 5 ) is a soy isoflavone with anti-cancer properties such as inhibition of cell growth, proliferation and tumor invasion, but effective dosage against hematopoietic malignant cells was not in non-toxic range. This property cause to impede its usage as chemotherapeutic agent. Therefore, this hypothesis raised that synthesizing biocompatible nanoparticle could assist to prevail this struggle. Methods Genistein covalently attached on Fe 3 O 4 nanoparticles decorated with carboxymethylated chitosan to fabricate Fe 3 O 4 -CMC-genistein in alkaline circumstance. This obtained nanoparticles were evaluated by TEM, DLS, FTIR, XRD and VSM and its anti-cancer effect by growth rate and MTT assays as well as flow cytometer on ALL cancer cell lines. Results Different evaluations indicated that the drug delivery vehicle had a mean diameter size around 12ƞm with well bounded components. This system presented high degree of magnetization and superparamagnetic properties as well as good water solubility. In comparison with pure genistein, significant growth inhibition on hematopoietic cancer cells in lower dose of genistein nano-conjugated onto Fe 3 O 4 -CMC. It increased long lasting effect of genistein in cancer cells also. Conclusion This delivery system for genistein could be remarkably promised and futuristic as biocompatible chemotherapeutic agent against hematopoietic malignant cells.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Natural Compound Pharmacology Studies · Synthesis of Organic Compounds · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Sharif University of Technology, Kish International Campus, Kish Island, Iran.
Molecular Medicine Research Center Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Department of Materials Science and Engineering, Sharif University of Technology, Tehran, Iran.
Department of Medical Genetics; Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Funding
Research Vice Chancellor of Hormozgan University for Medical Science
References (32)
Show source-provided references
1. 10.1016/S1470-2045(06)70793-810.1016/S1470-2045(06)70793-8 ↗
2. 10.2147/DDDT.S4303510.2147/DDDT.S43035 ↗
3. 10.1016/j.biomaterials.2009.04.02010.1016/j.biomaterials.2009.04.020 ↗
4. 10.1016/j.biomaterials.2009.06.00410.1016/j.biomaterials.2009.06.004 ↗
5. 10.1016/j.addr.2008.03.01810.1016/j.addr.2008.03.018 ↗
6. 10.2217/nnm.14.410.2217/nnm.14.4 ↗
7. Varshosaz J, Sadeghi-aliabadi H, Ghasemi S, Behdadfar B. Use of magnetic Folate-dextran-retinoic acid micelles for dual targeting of doxorubicin in breast Cancer. Biomed Res Int. 2013;2013:680712. 1:STN:280:DC%2BC2czhtlyitA%3D%3D10.1155/2013/680712 ↗
8. 10.5185/amlett.2010.310810.5185/amlett.2010.3108 ↗
9. 10.1016/j.colsurfb.2005.04.00910.1016/j.colsurfb.2005.04.009 ↗
10. 10.1016/S0960-894X(01)00285-210.1016/S0960-894X(01)00285-2 ↗
11. Hasegawa M, Yagi K, Iwakawa S, Hirai M. Chitosan induces apoptosis via caspase-3 activation in bladder tumor cells. Cancer Sci. 2001;92(4):459–466. 1:CAS:528:DC%2BD3MXktFeksbk%3D
12. 10.1166/jnn.2010.191310.1166/jnn.2010.1913 ↗
13. 10.5185/amlett.2010.310810.5185/amlett.2010.3108 ↗
14. 10.3892/ijo.2013.203210.3892/ijo.2013.2032 ↗
15. Zhang S, Wang Y, Chen Z, Kim S, Iqbal S, Chi A. Genistein enhances the efficacy of cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer cells. Prostate. 2013;73(15):1681–1689. 1:CAS:528:DC%2BC3sXhsFGgu7jK
16. 10.1371/journal.pone.007159210.1371/journal.pone.0071592 ↗
17. 10.3892/or.2013.289310.3892/or.2013.2893 ↗
18. 10.3390/ijms1503343210.3390/ijms15033432 ↗
19. 10.1002/pmic.20110065210.1002/pmic.201100652 ↗
20. 10.1080/01635581.2013.81029010.1080/01635581.2013.810290 ↗
21. 10.1158/1055-9965.EPI-09-100410.1158/1055-9965.EPI-09-1004 ↗
22. 10.1046/j.1365-2141.1996.d01-1694.x10.1046/j.1365-2141.1996.d01-1694.x ↗
23. 10.1016/j.jmmm.2014.09.04410.1016/j.jmmm.2014.09.044 ↗
24. 10.1016/j.ijpharm.2010.10.03810.1016/j.ijpharm.2010.10.038 ↗
25. 10.3390/molecules1807753310.3390/molecules18077533 ↗
26. 10.1186/2193-8865-3-7710.1186/2193-8865-3-77 ↗
27. 10.1021/bm061091g10.1021/bm061091g ↗
28. 10.1016/j.ijpharm.2013.03.02510.1016/j.ijpharm.2013.03.025 ↗
29. 10.1016/j.ijpharm.2012.01.04310.1016/j.ijpharm.2012.01.043 ↗
30. 10.1039/C4RA06618A10.1039/C4RA06618A ↗
31. 10.1016/j.jnutbio.2005.07.00510.1016/j.jnutbio.2005.07.005 ↗
32. 10.1016/j.lfs.2006.12.03110.1016/j.lfs.2006.12.031 ↗